Geron to Announce Third Quarter 2018 Financial Results on November 1, 2018
25 oct. 2018 06h00 HE
|
Geron Corporation
MENLO PARK, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that it will release its third quarter 2018 financial results after the market closes on...
Geron Corporation Reports Second Quarter 2018 Financial Results and Recent Company Events
31 juil. 2018 16h07 HE
|
Geron Corporation
MENLO PARK, Calif., July 31, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the three and six months ended June 30, 2018. Second Quarter and Year to...
Geron Reports Imetelstat Presentation at American Association for Cancer Research Annual Meeting
05 avr. 2017 07h30 HE
|
Geron Corporation
MENLO PARK, Calif., April 05, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced a poster presentation by Janssen Research & Development, LLC describing non-clinical data...
Geron Reports Imetelstat Presentations at American Society of Hematology Annual Meeting
06 déc. 2016 16h01 HE
|
Geron Corporation
MENLO PARK, Calif., Dec. 06, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced four presentations of exploratory preclinical and clinical data related to the imetelstat...
Geron Announces Initiation of Janssen Phase 2/3 Clinical Trial of Imetelstat in Myelodysplastic Syndromes
14 janv. 2016 07h30 HE
|
Geron Corporation
MENLO PARK, Calif., Jan. 14, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced the dosing of the first patient in a Phase 2/3 clinical trial to evaluate imetelstat in...
Dual Publications in the New England Journal of Medicine Highlight Transformative Potential of Imetelstat in Hematologic Myeloid Malignancies
02 sept. 2015 17h01 HE
|
Geron Corporation
MENLO PARK, Calif., Sept. 02, 2015 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced the publication of two papers in The New England Journal of Medicine (NEJM) in which the...